Login / Signup

Alarmin-painted exosomes elicit persistent antitumor immunity in large established tumors in mice.

Bingfeng ZuoHan QiZhen LuLu ChenBo SunRong YangYang ZhangZhili LiuXianjun GaoAbin YouLi WuRenwei JingQibing ZhouHaiFang Yin
Published in: Nature communications (2020)
Treating large established tumors is challenging for dendritic cell (DC)-based immunotherapy. DC activation with tumor cell-derived exosomes (TEXs) carrying multiple tumor-associated antigen can enhance tumor recognition. Adding a potent adjuvant, high mobility group nucleosome-binding protein 1 (HMGN1), boosts DCs' ability to activate T cells and improves vaccine efficiency. Here, we demonstrate that TEXs painted with the functional domain of HMGN1 (TEX-N1ND) via an exosomal anchor peptide potentiates DC immunogenicity. TEX-N1ND pulsed DCs (DCTEX-N1ND) elicit long-lasting antitumor immunity and tumor suppression in different syngeneic mouse models with large tumor burdens, most notably large, poorly immunogenic orthotopic hepatocellular carcinoma (HCC). DCTEX-N1ND show increased homing to lymphoid tissues and contribute to augmented memory T cells. Importantly, N1ND-painted serum exosomes from cancer patients also promote DC activation. Our study demonstrates the potency of TEX-N1ND to strengthen DC immunogenicity and to suppress large established tumors, and thus provides an avenue to improve DC-based immunotherapy.
Keyphrases
  • dendritic cells
  • mesenchymal stem cells
  • stem cells
  • binding protein
  • immune response
  • regulatory t cells
  • early stage
  • bone marrow
  • anti inflammatory